Tert-butyl N-[3-(methylamino)butyl]carbamate | 1782475-64-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Tert-butyl N-[3-(methylamino)butyl]carbamate
• CAS: 1782475-64-2
• 化学式: C₁₀H₂₂N₂O₂
• 分子量: 202.29
• InChiKey: RDMLKVWMUSZEGD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  50.4
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] 5-[5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES<br/>[FR] DÉRIVÉS DE 5-[5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL] ET COMPOSÉS ASSOCIÉS UTILISÉS COMME MODULATEURS POUR L'ÉPISSAGE DES ACIDES NUCÉIQUES ET POUR LE TRAITEMENT DE MALADIES PROLIFÉRATIVES
  申请人：REMIX THERAPEUTICS INC

  公开号：WO2022006543A1

  公开（公告）日：2022-01-06

  The present disclosure features compounds e.g. of formula (I-a) and similar compounds e.g. of formulae (l-g), (l-i), (l-j), (III), (lll-a), (III- b) and (IV) disclosed herein and other related compounds, and pharmaceutical compositions thereof. The present disclosure further discloses said compounds and their compositions for use in methods of modulating nucleic acid splicing, as well as said compounds for use in methods of treating e.g.: • proliferative diseases, such as e.g. cancer, benign neoplasms or angiogenesis, • neurological diseases or disorders, such as e.g. Huntington's disease, • autoimmune diseases or disorders, immunodeficiency diseases or disorders, lysosomal storage disease or disorder, cardiovascular diseases or disorders, metabolic diseases or disorders, respiratory diseases or disorders, renal diseases or disorders, or infectious diseases. Exemplary compounds are e.g. 5-[5-(piperidin-4-y l)thieno[3,2- c]pyrazol-2-yl]indazole and 5-[2-(piperidin-4-yl)-[1,2,4]triazolo[3,2-b] [1,3]thiazol-5-yl]indazole derivatives and related compounds.

  本公开涉及化合物，例如式(I-a)的化合物以及类似的化合物，例如式(l-g)，(l-i)，(l-j)，(III)，(lll-a)，(III-b)和(IV)以及其他相关化合物及其药物组合物。本公开进一步揭示了所述化合物及其组合物用于调节核酸剪接的方法，以及所述化合物用于治疗的方法，例如： •增殖性疾病，例如癌症、良性肿瘤或血管生成， •神经疾病或障碍，例如亨廷顿病， •自身免疫疾病或障碍，免疫缺陷疾病或障碍，溶酶体贮积病或障碍，心血管疾病或障碍，代谢性疾病或障碍，呼吸系统疾病或障碍，肾脏疾病或障碍，或传染病。示例化合物包括例如5-[5-(哌啶-4-基)噻吩[3,2-c]吡唑-2-基]吲唑和5-[2-(哌啶-4-基)-[1,2,4]三唑噻吩[3,2-b][1,3]噻唑-5-基]吲唑衍生物及相关化合物。
• 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS
  申请人：PFIZER INC.

  公开号：US20170029390A1

  公开（公告）日：2017-02-02

  The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

  本发明提供了部分I式化合物及其药学上可接受的盐；制备所用的中间体；以及含有这种化合物或盐的组合物，以及它们用于治疗MAGL介导的疾病和障碍，包括但不限于疼痛，炎症性疾病，创伤性脑损伤，抑郁症，焦虑症，阿尔茨海默病，代谢紊乱，中风或癌症。
• US9845301B2
  申请人：——

  公开号：US9845301B2

  公开（公告）日：2017-12-19